These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 30499237)

  • 21. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
    Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
    Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
    Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
    Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
    Scott R; Morgan J; Zimmer Z; Lam RLH; O'Neill EA; Kaufman KD; Engel SS; Raji A
    Diabetes Obes Metab; 2018 Dec; 20(12):2876-2884. PubMed ID: 30019498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
    Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
    Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial.
    Gu T; Ma J; Zhang Q; Zhu L; Zhang H; Xu L; Cheng J; Shi B; Li D; Shao J; Sun Z; Zhong S; Bi Y; Zhu D
    Diabetes Obes Metab; 2019 Apr; 21(4):939-948. PubMed ID: 30520221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
    Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
    Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus.
    Hu S; Deng X; Ma Y; Li Z; Wang Y; Wang Y
    Appl Health Econ Health Policy; 2021 Jan; 19(1):69-79. PubMed ID: 32783086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Roussel R; Duran-García S; Zhang Y; Shah S; Darmiento C; Shankar RR; Golm GT; Lam RLH; O'Neill EA; Gantz I; Kaufman KD; Engel SS
    Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Jabbour SA; Hardy E; Sugg J; Parikh S;
    Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
    Mathieu C; Herrera Marmolejo M; González González JG; Hansen L; Chen H; Johnsson E; Garcia-Sanchez R; Iqbal N
    Diabetes Obes Metab; 2016 Nov; 18(11):1134-1137. PubMed ID: 27385192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
    Del Prato S; Rosenstock J; Garcia-Sanchez R; Iqbal N; Hansen L; Johnsson E; Chen H; Mathieu C
    Diabetes Obes Metab; 2018 Jun; 20(6):1542-1546. PubMed ID: 29446523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
    Tinahones FJ; Gallwitz B; Nordaby M; Götz S; Maldonado-Lutomirsky M; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2017 Feb; 19(2):266-274. PubMed ID: 27762093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.
    Rosenstock J; Gross JL; Aguilar-Salinas C; Hissa M; Berglind N; Ravichandran S; Fleming D
    Diabet Med; 2013 Dec; 30(12):1472-6. PubMed ID: 23802840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
    Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
    Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
    Kim SS; Kim IJ; Lee KJ; Park JH; Kim YI; Lee YS; Chung SC; Lee SJ
    J Diabetes; 2017 Apr; 9(4):412-422. PubMed ID: 27229178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
    Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
    Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
    Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study.
    Jeong IK; Choi KM; Han KA; Kim KA; Kim IJ; Han SJ; Lee WY; Yoo SJ
    Diabetes Obes Metab; 2024 Nov; 26(11):5065-5077. PubMed ID: 39223856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.